View Clinical Trial (Medical Research Study)

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth - NCT00413335-06520(Clinical Trial 158863)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New Haven
State:  
CT
Zip Code: 06520
Conditions: Obesity - Impaired Glucose Tolerance - Type 2 Diabetes Mellitus
Purpose: The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.
Study summary: Impaired Glucose Tolerance (IGT) is a prelude to diabetes, which is increasing in prevalence in obese children and adolescents with marked obesity. This condition tends to progress to Type 2 Diabetes Mellitus (T2DM) at an alarmingly rapid tempo. The increased prevalence of childhood and adolescent obesity and greater risk of IGT, and progression to diabetes, in this population set the stage for a series of studies aimed at understanding the metabolic phenotype and natural history of pre-diabetes in obese youth. We found that obese children and adolescents with IGT are characterized by marked insulin resistance related to altered lipid partitioning, favoring lipid deposition in the visceral and intramyocellular compartment. Furthermore, we found an impairment of the acute insulin response in these youngsters. Follow-up revealed a rapid deterioration from IGT to frank diabetes. Based on these studies, there is a strong rationale for changing the balance between visceral and subcutaneous fat and muscle lipid content in a more favorable pattern in order to improve insulin sensitivity. The primary objective of this study is to determine, in a group of ethnically diverse children and adolescents with IGT, whether treatment with rosiglitazone leads to improvements in insulin sensitivity and glucose tolerance. Secondary objectives are to determine whether rosiglitazone is safe and well tolerated.
Criteria: Inclusion Criteria: - Good general health - Aged 10 to 18 yrs (females: Tanner stage II-V;and males:testes size>6ml) - IGT based on 2-hr plasma glucose>140mg/dl and <200mg/dl during an OGTT. Exclusion Criteria: - Baseline creatinine>1.0mg - AST and ALT>2.5 ULN - Anemia (Hct<30) - Pregnancy (females must have a negative urine pregnancy test during the study) - Cardiac or pulmonary or other significant chronic illness - Plans to increase the frequency or intensity of a regular exercise program - Psychiatric disorder or substance abuse of anorexic agents.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: December 29, 2009
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.